Key Highlights

  • Regeneron reported second-quarter 2026 sales with Dupixent reaching around $6 billion quarterly.
  • The newer Eylea HD formulation and cancer drug Libtayo contributed to overall growth.
  • The company advanced its pipeline, including its first gene-therapy approval.
  • Original Eylea faces competition from cheaper biosimilar copies, pushing patients toward the longer-acting Eylea HD.

Regeneron (NASDAQ:REGN) has built a formidable Business on a handful of blockbuster medicines, but its future depends on what comes next. As its older products face growing competition, pipeline progress, turning laboratory science into approved, saleable drugs, is crucial to its Nasdaq 100 healthcare story.

What Regeneron Does

Regeneron is a biotechnology company that discovers, develops and sells medicines for a range of serious conditions. It sits in the healthcare sector. Its business has been anchored by two hugely successful products: Eylea, an eye treatment for conditions that cause blindness, and Dupixent, a treatment for inflammatory diseases such as eczema and asthma that it shares with a partner. It is known for its scientific strength and its technology for discovering new antibody-based medicines.

Pipeline and Franchise in Focus

Recent results show both the strength of its franchise and the importance of the pipeline. In the second quarter of 2026 Regeneron reported strong sales, with Dupixent reaching around six billion US dollars in quarterly sales and its newer Eylea HD formulation and cancer drug Libtayo contributing to growth, and it advanced its pipeline, including its first gene-therapy approval. The context matters: the original Eylea faces competition from cheaper copies, so Regeneron has been shifting patients to the longer-acting Eylea HD and relying on Dupixent's continued growth, while developing new medicines to sustain the company well into the future. Pipeline progress is what determines whether growth continues as older products mature.

Why it Matters for the Nasdaq 100

Regeneron offers the index exposure to biotechnology and to the value created by pharmaceutical innovation. Its results reveal how well it is defending its key franchises and advancing new medicines. As a large, profitable member of the benchmark, it provides Diversification away from technology, and its progress is a useful read on the biotechnology industry's ability to sustain growth by continually renewing its portfolio of drugs.

Defending and Renewing at Once

Regeneron's challenge is a common one in pharmaceuticals, and worth understanding: it must defend its existing blockbusters while developing the next generation. Its original Eylea faces competition from biosimilars, cheaper near-copies that erode sales, so Regeneron has worked to move patients onto Eylea HD, which lasts longer and is protected for longer. Dupixent, meanwhile, has kept growing and expanding into new uses, providing a powerful engine. But no drug lasts forever, so the company must keep advancing new medicines, in areas from cancer to gene therapy, to replace Revenue that will eventually decline. How successfully it manages this constant cycle of defending and renewing determines whether it can keep growing, which is why every pipeline milestone draws such attention.

The Risks to Weigh

Drug development is uncertain, and pipeline setbacks can happen even late in testing. Competition to Eylea from Biosimilars is a real and present threat. Dupixent is shared with a partner, so Regeneron does not keep all its profits. Pricing pressure and regulation add uncertainty, and the shares can move sharply on clinical or competitive news. Reliance on a small number of key products concentrates risk.

Turning Science Into the Next Blockbuster

Readers should track sales of Dupixent and the Eylea franchise, including the shift to Eylea HD, since these drive current revenue, and watch how well Eylea HD holds off biosimilar competition. Clinical progress across the pipeline, including in cancer and gene therapy, indicates future growth. Commentary on pricing and competition reveals external pressures. Margins and cash generation support Investment and returns. Finally, watch pipeline milestones closely, because Regeneron's ability to keep growing rests on continually turning its scientific strength into new approved medicines. It is worth watching the uptake of medicines in oncology and gene therapy, because these determine whether Regeneron can build its next generation of blockbusters. Any development affecting Dupixent, its most important product, would carry outsized weight.